Article

What Can You Do To Overcome Immunogenicity And Immunotoxicity Assessment Challenges?

iStock-503258063-microscope-research-lab

The last decade in drug development has given rise to many different types of new therapies that offer great potential in improving patient care. However, the increasing complexity of these advanced pharmaceuticals makes it incredibly challenging to bring them to market, with 89% of novel drugs failing human clinical trials.1 While there are many reasons this could occur, approximately half of these failures were due to unanticipated human toxicity.1 In rare cases, unwanted immune responses have led to the death of clinical trial participants.2

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Drug Discovery Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: